Ucb SA
XBRU:UCB

Watchlist Manager
Ucb SA Logo
Ucb SA
XBRU:UCB
Watchlist
Price: 248.2 EUR 0.28% Market Closed
Market Cap: 48.3B EUR

P/E
Price to Earnings

35.4
Current
37
Median
21.7
Industry
Lower than median
Higher than industry value

The Price to Earnings (P/E) ratio shows how much investors are willing to pay for each dollar of a company’s earnings. It’s calculated by dividing the company’s market value by its net income.

P/E
35.4
=
Market Cap
47.2B EUR
/
Net Income
1.3B EUR
All Countries
Close
Market Cap P/E
BE
Ucb SA
XBRU:UCB
47.2B EUR 35.4
US
Eli Lilly and Co
NYSE:LLY
943.6B USD 51.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP -15 783.5
US
Johnson & Johnson
NYSE:JNJ
485.1B USD 19.3
CH
Roche Holding AG
SIX:ROG
253B CHF 26.8
UK
AstraZeneca PLC
LSE:AZN
210.6B GBP 29.8
CH
Novartis AG
SIX:NOVN
204.6B CHF 17.6
US
Merck & Co Inc
NYSE:MRK
246.1B USD 12.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 12.8
IE
Endo International PLC
LSE:0Y5F
202.5B USD -69.3
US
Pfizer Inc
NYSE:PFE
146.5B USD 14.9
Earnings Growth PEG
BE
Ucb SA
XBRU:UCB
Average P/E: 24.5
35.4
34%
1
US
Eli Lilly and Co
NYSE:LLY
51.2
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.8
38%
0.8
CH
Novartis AG
SIX:NOVN
17.6
17%
1
US
Merck & Co Inc
NYSE:MRK
12.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
29%
0.5

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
hidden
2-Years Forward
P/E
hidden
3-Years Forward
P/E
hidden